Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavaud, Pernelle, Dumont, Clément, Thibault, Constance, Albiges, Laurence, Baciarello, Giulia, Colomba, Emeline, Flippot, Ronan, Fuerea, Alina, Loriot, Yohann, Fizazi, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768840/
https://www.ncbi.nlm.nih.gov/pubmed/33488778
http://dx.doi.org/10.1177/1758835920978134
Descripción
Sumario:Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.

Ejemplares similares